Pegfilgrastim
DB00019
Approved Indication
Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant.
2
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase.
Details
DrugBank ID
DB00019 ↗
Approval Date
2002-04-01
Molecular Weight
— g/mol
Drug Class
Other
ATC Codes
L03AA13
Synonyms
Peg-filgrastim
ChEMBL
CHEMBL1201568 ↗
Drug References (DrugBank)